A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Rosnilimab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms ROSETTA STUDY
- Sponsors AnaptysBio
Most Recent Events
- 31 Mar 2025 Last checked against ClinicalTrials.gov record.
- 12 Feb 2025 According to an AnaptysBio media release, top-line Week 12 Phase 2 data for rosnilimab in UC, now expected in Q4 2025.
- 14 Aug 2024 According to an AnaptysBio media release, company announced the pricing of an underwritten offering of 2,750,498 shares, the gross proceeds from this offering are expected to be approximately $100 million. The proceeds intended to be used primarily to accelerate and support the enablement of Phase 3 trials for ANB032in Phase 2b development in atopic dermatitis, rosnilimab in Phase 2b development in rheumatoid arthritis and Phase 2 development in ulcerative colitis.